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Abstract: 
Disc-shaped nanoparticles with high aspect ratios have been reported to show preferential 
cellular uptake in vitro by mammalian cells. However, engineering and producing such disc-
shaped nanoparticles are often complex. This study reports for the first time the use of a single, 
approved pharmaceutical excipient to prepare stable disc-shaped nanoparticles with a high 
aspect ratio via a simple, organic solvent free process. These disc-shaped nanoparticles were 
formed by fragmentation of stearoyl macrogol-32 glycerides (Gelucire 50/13) hydrogels. The 
nanoparticles showed good physical stability as a result of their outer coating of polyethylene 
glycol (PEG) that is a part of Gelucire composition. Using lysozyme as a model hydrophilic 
protein, these nanoparticles demonstrated a good loading capacity for hydrophilic 
macromolecules, mainly via surface adsorption. As a result of the higher hydrophobicity of the 
core of the nano-discs, the loading efficiency of hydrophobic model components, such as 
Coumarin-6, was significantly increased in comparison to the model hydrophilic compound. 
These Gelucire nano-discs exhibited no cytotoxicity at the tested level of 600µg/ml for Caco-
2 cells. Rapid in vitro cellular uptake of the disc-shaped nanoparticles by Caco-2 and H292 
epithelial cells was observed. This rapid internalisation was attributed to the high aspect ratio 
of the disc-shape nanoparticles which provides a high contact surface area between the particles 
and cells and may lower the strain energy required for membrane deformation during uptake. 
The results of this study demonstrate the excellent potential of Gelucire nano-discs as effective 
nanocarriers for drug delivery and which can be manufactured using a simple solvent- free 
process.  
Keywords: drug delivery, polyoxyethylene glycol glycerides, disc-shape nanoparticles, 
cellular uptake
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Introduction 
Nanoparticles have been studied intensively for targeted drug delivery and have received some 
success in diseases such as cancer (Wang et al., 2012). Anti-cancer efficacies of drug-loaded 
nanoparticles have been associated with the particle size and surface properties of the particles 
(Mitragotri, 2009). The conventional shape of the majority of nanoparticles studied and 
currently used in the clinic is spherical. In general, spherical nanoparticles with a diameter 
below 100 nm with surface modifications such as PEG or other surface ligand attachments 
show an enhanced permeation and retention effect (EPR), reduced surface plasma protein 
adsorption, prolonged in vivo circulation time and better tissue targeting (Alexis et al., 2008; 
Gref et al., 1994). However, recently an increasing number of studies have highlighted the 
importance of particle shape in the fate (such as circulation time, cellular uptake and 
biodistribution), cytotoxicity and potential efficacy of therapies that use nanoparticles (Truong 
et al. 2015; Agarwal et al., 2013; Barua et al., 2013; Sharma et al., 2010; Muro et al., 2008; Lu 
et al., 2013; Oh et al., 2010; Chu et al., 2014). 
 
Among the different shapes of nanoparticles available, disc-shaped particles have shown some 
unique behaviour. For example, Agarwal and co-workers (2013) have reported the preferential 
cellular uptake of disc-shaped hydrogel nanoparticles by mammalian cells in comparison to 
spherical and rod-shaped hydrogel nanoparticles. The cytotoxicity of poly(3,4-
ethylenedioxythiophene) nanoparticles with different shapes demonstrated increased 
cytotoxicity and apoptosis with decreasing the aspect ratios of the particles for the model cell 
lines studied (Hu et al., 2013). For drug delivery purposes, most reported disc-shaped 
nanoparticles have been made of PEG and polystyrene (Truong et al. 2015). These particles 
have shown high cellular uptake (Agarwal et al., 2013; Barua et al., 2013; Sharma et al., 2010; 
Muro et al., 2008). A full understanding of the mechanisms behind the enhanced in vitro 
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performance of disc-shaped nanoparticles is still lacking and there are limited reports of the 
types of materials and scalable preparation methods that can be used for the manufacture of 
disc-shaped nanoparticles (Truong et al., 2015). This study reports proof-of-concept results of 
the use of FDA approved, polyoxyethylene glycol glycerides, commercially known as Gelucire 
50/13 to prepare disc-shaped gel nanoparticles using a scalable preparation method that does 
not require organic solvents or other additional processing aids.  
 
Gelucire 50/13 is a mixed glycerides based material esterified with PEG. The rationale of 
choosing Gelucire 50/13 to prepare nanoparticles is based on both the constituent ingredients 
of this material and the bulk properties of Gelucire gels. The ability of glycerides based 
materials, such as the glycerylmonooleate (GMO), to form submicron particles (often with the 
aid of solvents) has been established (Gustafsson et al., 1996). However in order to obtain 
stable nanoparticle suspension formulations, the addition of stabilisers, such as surfactants, 
sugars, polymers (i.e. Poloxamer) and PEG, are often required (Spicer et al., 2001; 
Gustafssonet al., 1997). Gelucire intrinsically contains free PEG and has been used as a 
stabiliser of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) (Date et 
al., 2011). The presence of PEG in Gelucire may also provide the surface modification required 
to increase the half-life of nanoparticles in the bloodstream by reducing the metabolic 
degradation and the immunogenicity of the nanoparticle (Almeida and Souto, 2007). Therefore 
in theory, the 8% free PEG 1500 and the small proportions of monoacyl and diacyl PEG in 
Gelucire 50/13 may act as an intrinsic stabiliser if used for the production of nanoparticles, 
suggesting that Gelucire 50/13 gels would be good candidates for producing gel nanoparticles. 
However, to date, there is no published work that has explored the ability of using Gelucire 
50/13 alone to form stable nanoparticles.  
 
  5 
The unique bulk properties of Gelucire 50/13 based gels include their semi-liquid crystalline 
structures, which evolve from lamellar to hexagonal and cubic phases depending on the water 
content of the gels (Qi et al., 2010; Codoni et al., 2015). For the gels with intermediate to high 
water contents structural analyses suggest the possibility of the co-existence of multiple liquid 
crystalline phases. Our previous rheological studies have shown the formation of cross-linked 
or entangled structures depending on the water content of the gels (Codoni et al., 2015). 
Detailed analysis of the microstructures of the gels using SEM, DSC and relaxometry NMR 
confirmed the existence of water compartments (such as aqueous channels and domains) in the 
interior of the gels (Codoni et al., 2015). This ordered network structure of the gels offers the 
potential of forming nanoparticles by mechanical fragmentation.  
 
The aim of this study was to develop a robust method for preparing nanoparticles based on 
Gelucire 50/13 gels alone. Lysozyme was employed as a model hydrophilic protein and the 
characterisation of the lysozyme-loaded nanoparticles as well as the encapsulation efficiency 
and the retained activity of lysozyme were assessed. Coumarin-6 was used as a highly 
hydrophobic model component for comparing the loading efficiency of materials with different 
hydrophobicities. In vitro cytotoxicity of the nanoparticles was assessed using two human 
epithelial cell model lines, the lung cancer cell line (H292) and the human intestinal cell line 
(Caco-2). The cellular uptake of the gel nanoparticles was also evaluated using Caco-2 cells. 
Experimental 
Materials 
Stearoyl macrogolglycerides (Gelucire® 50/13) was kindly donated by Gattefossé SAS (St 
Priest, France). Hen egg-white lysozyme (Sigma Aldrich, Gillingham, UK) was used the 
chosen model protein. Ultrapure type I water (Milli-Q grade, 18 MΩ.cm at 25 °C) produced by 
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Barnstead Nanopure system (Thermo Scientific, UK) was used for all the sample preparations. 
Coumarin 6 (3-(2’-Benzothiazolyl)-7-diethylaminocoumarin) was used as lipophilic 
fluorescent dye (Acros Organics, USA). Micrococcus lysodeikticus cells were purchased from 
Sigma Aldrich, UK. Foetal calf serum (FCS) was purchased from Biosera, UK. DMEM 
(Dulbecco’s Modified Eagles Medium with glucose and glutamine), 10,000 U/ml penicillin 
and 10,000 μg/ml streptomycin, 0.25% trypsin-EDTA were purchased from Invitrogen, UK. 
Non-essential amino acids and sodium pyruvate were purchased from Thermo Fisher 
Scientific,UK. For the MTS assay the CellTilter96® AQueous One Solution (Promega) was used. 
  
Preparation of protein loaded gel nanoparticles  
The gel nanoparticles were prepared by fragmentation of Gelucire 50/13 bulk gel in water. A 
range of Gelucire 50/13 gels with water contents from 10% to 90% (w/w) were prepared by 
melting Gelucire at 62 ± 2 °C. The appropriate amount of water, heated to the same temperature, 
was added to the melted Gelucire. The mixtures were removed from the heat and a hand-held 
disperser (Power Gen 125, Fischer Scientific, UK) was used for agitating the mixture at 8000 
rpm for 2-3 minutes. After adding water to the bulk gel with a weight ratio of 9:1 gel: water, 
bulk gel fragmentation was performed by vortexing the gel using a hand-held disperser (Ultra 
Turrax T10 basic, IKA, Germany) at 30000 rpm for 5 minutes. The nanoparticle dispersion 
with a final concentration of 2% w/w gel and 98% w/w water was homogenised by passing it 
five times through a high-pressure homogeniser (EmulsiFlex-C5, Avestin, Ottawa, Canada) at 
the pressure of approximately 12000 psi and at room temperature. The nanoparticles made from 
the bulk gels with 40, 50, and 60% water contents were labelled as F1 to F3, respectively (as 
seen in Table 1). The formulations were stored at 4 °C and at room temperature for the physical 
stability studies.  
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Preparation of the lysozyme-loaded gel nanoparticles followed the same procedure for 
fragmenting lysozyme-loaded bulk gels. Lysozyme was incorporated into the gels with 40% to 
60% (w/w) water contents by pre-dissolving lysozyme in the water phase. The lysozyme 
concentrations in the gel formulations were fixed at 3% (w/w) for all formulations. The final 
concentration of lysozyme in the nanoparticle dispersion is 0.06 mg/ml. The components of the 
formulations are listed in Table 1. 
Table 1. Water content of the bulk gels and their corresponding gel nanoparticles  
Protein-free bulk gel 
formulations 
(water, w/w) 
Gel nanoparticle 
formulations 
Lysozyme-loaded bulk gel 
formulations 
(% water, w/w) 
Gel nanoparticle 
formulations 
40 F1 40 F1-LYS 
50 F2 50 F2-LYS 
60 F3 60 F3-LYS 
 
Dynamic Light Scattering (DLS) 
The size of the nanoparticles in aqueous suspension was analysed with a DLS (Zetasizer Nano, 
Malvern Instruments Ltd, Malvern, UK) in backscattering mode (173°). The samples were 
equilibrated at 37 ° C for 15 minutes and three acquisitions were taken for each sample. The 
samples were analysed in triplicate. The physical stability tests of the nanoparticles suspension 
formulations were performed on the formulations stored at room temperature and at 4 °C over 
a period of time for 4 months. The size distribution obtained is derived from the intensity 
calculation (NNLS) performed by the Zetasizer software, 6.20. All measures were repeated 4-
6 times.  
Atomic force microscopy (AFM) 
The sizes and shapes of the selected lysozyme-free and lysozyme-loaded nanoparticle 
formulations (F1 and F3) were analysed using a Caliber atomic force microscope (AFM) from 
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Bruker AFM (UK). The formulations were diluted 1:10 with Milli-Q water and 3 μl of the 
dilution were dropped on a mica film and left to dry for 15 minutes. The film was then rinsed 
with water and dried with compressed air. As the nanoparticles show little tendency for 
aggregation (see stability results), it was assumed that the dilution and drying process applied 
would not lead to significant changes in the sizes of the nanoparticles. Five to ten sites on each 
sample were analysed in order to assess the level of homogeneity of the formulations. 
Cryo-Transmission electron microscopy (Cryo-TEM) 
Cryo-TEM was used to assess the size and shape of the gel nanoparticle formulations F1 and 
F3. The nanoparticles were placed on the microscope copper grid (coated with a perforated 
polymer film) in order to form a thin aqueous film. The excess of liquid was removed by 
blotting with a filter paper. The film was then immersed in a cooling medium (ethane) held at 
a temperature just above its freezing point. The film rapidly vitrified without crystallisation. 
The grid with the vitrified film was transferred to a Zeiss EM 902 A transmission electron 
microscope (Oberkochen, Germany). The sample was held at liquid nitrogen temperature and 
at a controlled humidity environment during the measurement. All observations were made in 
zero-loss bright-field mode and at an accelerating voltage of 80 kV. The nanoparticles 
suspensions were analysed non-diluted and at a maximum magnification of 50000x.  
Encapsulation efficiency (%EE) 
The centrifugation method was chosen to assess the encapsulation efficiency of lysozyme in 
the nanoparticle formulations. A 3 ml sample of the nanoparticle aqueous suspension was 
loaded in the centrifugal filter tubes (Amicon Ultra-4, Millipore) with regenerated cellulose 
membrane (MWCO 30 kDa) and centrifuged at 2000 g (Heraeus, Thermo Scientific, UK) for 
a period of time that allowed the collection of 2.5 ml of filtrate solution. The filtrate solution 
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collected after centrifugation was analysed with a UV spectrometer to assess the quantity of 
lysozyme. The quantification of the encapsulation efficiency was calculated using the 
following formula 
                      Eq. 1 
where F lyst is the total amount of lysozyme loaded in the formulation and F lysc is the amount 
of free lysozyme recovered in the filtrate after centrifugation. 
Prior to the analysis, a calibration curve of lysozyme in aqueous solution was constructed. A 
lysozyme aqueous solution with a concentration of 0.9 mg/ml (0.09 % w/v) was prepared as 
the stock solution. 1, 2, 3, 4 and 5ml aliquots of the stock solution were then individually 
transferred in 10 ml volumetric flasks to prepare dilutions of lysozyme solutions with 
concentrations of 0.09, 0.18, 0.27, 0.36 and 0.45 mg/ml, respectively. Three repetitions were 
used and the average UV absorbance values of the solutions were plotted against the protein 
concentrations. The measurements were taken using a UV spectrophotometer (Lambda 35, 
Perkin-Elmer, USA). The wavelength of maximum absorbance, λmax, 280 nm was used for 
the measurements. All encapsulation measurements for each formulation were performed at 
least in triplicate.  
Lysozyme activity assay  
The biological activities of lysozyme in solution and formulations were tested by measuring 
the degree of lysis induced by lysozyme on micrococcus lysodeikticus cells using a 
turbidimetry test described by Shugar (1952). The test is based on the comparison of the 
decrease in turbidity of the suspension and therefore the decrease of absorbance at 450 nm of 
a lysozyme solution with the known activity. A 0.015% (w/v) micrococcus lysodeikticus cell 
t
ct
F lys
F lysF lys
EE%


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suspension was prepared using 66 mM potassium phosphate buffer (pH=6.27) at 25 °C. 
Immediately before the test, a lysozyme buffer solution was prepared to contain 400 U/ml of 
the protein as control. The lysozyme-loaded nanoparticle formulations with a lysozyme 
concentration equal to 0.6 mg/ml were diluted with the phosphate buffer to obtain a final 
concentration of lysozyme equal to 0.01 mg/ml.  
The tests were performed by pipetting 2.5 ml of the substrate (micrococcus lysodeikticus) into 
a quartz cuvette and leaving it to equilibrate at 25 °C for five minutes. A 100 µl sample of the 
phosphate buffer (for the blank control) or the diluted nanoparticle formulation was then added 
and mixed by inversion. The absorbance of the tested solution at 450 nm was measured every 
10 seconds over a period of 5 minutes. The decreases in absorbance were plotted against the 
time. The biological activity of lysozyme expressed in units/ml was calculated according to the 
protocol described by Shugar (1952). 
Circular Dichroism (CD) 
CD spectroscopy was used to study the changes in the lysozyme conformation after 
incorporation into the gel nanoparticle formulations. CD spectra were acquired in the near UV 
(240-500 nm) for lysozyme aqueous solution (0.6 % w/w) and for lysozyme-loaded 
nanoparticles dispersions with lysozyme concentration of 0.6 mg/ml (w/w). The concentration 
of the lysozyme in the nanoparticles suspension and in the aqueous solution was fixed at 0.6 
mg/ml. The tests were performed in triplicate by using a JASCO J-810 spectropolarimeter 
(Tokyo, Japan). A quartz cuvette with 10 mm pathlength was used. 
In vitro cytotoxicity and cellular uptake studies 
In vitro cytotoxicity of the unloaded nanoparticle formulation F2 was tested by using a model 
human lung epithelial cell line, H292 and human colon epithelial cell line, Caco-2 (from 
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ECACC). Both cell types were cultured in RPMI 1640 media containing 10% foetal calf serum, 
100 U/ml penicillin, 100µg/ml streptomycin and 2mM L-glutamine. Cells were maintained 
between 0.3-1 x106/ml at 37ºC and 5% CO2 and detached from culture flasks with 0.25% 
trypsin-EDTA. The nanoparticles were prepared from the bulk gel with 40% water and the 
dispersion had a final lipid concentration of 12 mg/ml. Caco-2 and H-292 cells were plated at 
4 x 103/100 µl in 96 well plates and a range of dilutions of the formulation F2 (600, 300, 200, 
150, 120, and 100 μg/ml) were added to the cells for 24 or 48h. Cell viability was measured by 
MTS assay as previously described (Howell et al, 2012) or by trypan blue exclusion using 0.4% 
trypan blue (Sigma).  
The fluorescently labelled Gelucire 50/13 gel nanoparticles used for the cellular uptake study 
were prepared using the heating method. The fluorescent dye (Coumarin-6) was added to the 
melted lipid and mixed using a magnetic stirrer. When the dye was completely dissolved in the 
molten lipid, water heated to  the same temperature as the  molten lipid was added and the 
nanoparticles were prepared following the same steps described earlier. The concentration of 
Coumarin-6 in the gels is 0.001% w/w. The fluorescently labelled gel nanoparticles were 
prepared by following the same procedure described above. Caco-2 cells were plated at 1 x 105 
cells/ml in 6 well plates and adhered overnight. The gel nanoparticles were added for various 
times up to 24 h and examined by microscopy using a Leica MS GmbH fluorescence 
microscope and Leica Application Suite software (Leica, Mannhein, Germany). 
Results and discussion 
Fabrication of disc-shaped gel nanoparticles  
The simple three-step aqueous fabrication process of the disc-shaped Gelucire nanoparticles is 
shown in Figure 1. A room temperature lysozyme solution was added into pre-melted Gelucire. 
With vigorous agitation of the mixture at room temperature, it gradually set into a bulk gel. 
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Additional amount of water was added to the bulk gel with the ratio of 9:1 (w/w) and electrical 
disperser was used to break down the bulk gel to coarse particles. Gelucire gel nanoparticles 
were then obtained via high-pressure homogenisation of the coarse particles. Two key variables 
for the nanoparticle formulations are the total water content in the bulk gel and the lysozyme 
loading. It can be seen in Figure 2 that the total water content of the bulk gel has a clear impact 
on the processability and particle size of nanoparticles. Gels with higher water content have a 
smaller mean particle size, but all formulations have two populations of sizes with 
polydispersity PDI value ≥ 0.3. More importantly, a higher water content of the bulk gel also 
leads to the production of nanoparticles with sizes that are independent of repeated processing 
by high-pressure homogenisation. This is likely to be a result of different self-assembled 
microstructures of the bulk gels with different water contents. As discussed in our previous 
work, the SAXS results of gels with intermediate water content (40-60%) indicated the 
presence of cubic and hexagonal configurations, whereas the gels with low water contents tend 
to predominantly consist of a lamellar structure (Qi et al., 2010). The 3D assembled structure 
of the gels with cubic and hexagonal molecular arrangements have a greater degree of freedom 
and higher degree of chaoticity within the structure which may facilitate their natural 
breakdown into nanoparticles, whereas lamellar gels have a much denser 2D structure and as 
such the particle size of the fragmented lamellar based bulk gel may be progressively reduced 
by repeated high-pressure homogenisation.  
  13 
 
Figure 1. Schematic illustration of the fabrication process of lysozyme-loaded disc-shaped gel 
nanoparticles 
 
DLS was used in the first instance to measure the hydrodynamic particle size of the gel 
nanoparticles. For lysozyme-free nanoparticles, F1 showed significant reduction in particle size 
with increasing the homogenisation cycles from 1 to 3. After 5 cycles of homogenisation, the 
particle size remained constant at approximately 120 nm with a small population of particles 
at 20 nm (Figure 2). A clear bimodal distribution was observed for the F2 and F3 formulations 
with the main population being between 120-200 nm, and the second population being about 
20 nm. The presence of lysozyme increased the polydispersity and the sizes of the main 
population of the nanoparticles in comparison to the corresponding unloaded nanoparticles 
(Figure 3). 
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Figure 2. Changes of size distribution (d.nm) of the nanoparticle formulations F1, F2 and F3 
prepared by being passed through the high-pressure homogeniser with different number of 
cycles (n≥3).  
 
Figure 3. DLS correlation functions of the nanoparticle formulations (a) without and (b) loaded 
lysozyme measured at 37 °C. 
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Although the DLS can provide estimation of the hydrodynamic diameter of the nanoparticles, 
the analysis is based on the assumption of the particles being spherical. Therefore, in order to 
obtain more detailed information of the shape of the nanoparticles, cryo-TEM and AFM 
analyses were carried out. An example cryo-TEM image of F3 formulations is shown in Figure 
4. It is clear that the Gelucire nanoparticles have low-contrast to the surrounding media due to 
the presence of PEG chain which is invisible to the electron beam. This has been documented 
previously in the literature (Zetterberg et al., 2011), nevertheless the disc-like shape of the 
nanoparticles with the disc-face ranging between 50 and 300 nm and the disc-edge thickness 
ranging from 7-10 nm can be identified in the images. The low thickness of the discs in 
comparison to the dimensions of the disc-face of the nanoparticles gives the high aspect ratio 
(the ratio between the longer and short dimensions of the 2D object) of these nano-discs. More 
than 100 nanoparticles from each formulation were analysed and the diameter of the disc-face 
of the nanoparticles was determined using ImageJ 1.46r software. Histograms of the frequency 
(number of particles within a certain size range) versus the particle size were plotted using 
OriginPro 8. It can be seen that a high proportion of particles have a disc-face diameter between 
150-300 nm. This is in good agreement with the DLS results.  
 
Figure 4. (a) Example cryo-TEM image and (b) histogram of the particle size distribution of 
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the F1 formulation, measured from cryo-TEM images (plotted using frequency versus size 
interval).  
The 3D shape information of the nanoparticles was further studied using AFM. Tapping mode 
was used for all measurements, in order to minimise the damage of the soft Gelucire 
nanoparticles. As seen in Figure 5, using topographic analysis, the thickness and diameter of 
individual disc-shaped particles can be revealed. The data is summarised in Table 2, where all 
nanoparticles show high aspect ratios (X/Y:Z) of between 28:1 to 9:1, with F1 nanoparticles 
having the highest aspect ratio. The disc-face of F1 and F2 are largely circular in shape, whereas 
that of F3 shows a more elliptical shape. Lysozyme loading led to an increase in all of the 
dimensions of the particles. The sizes measured by DLS and cryo-TEM are slightly bigger than 
the ones obtained by AFM. This is likely to be due to the drying step of the samples preparation 
of AFM measures led to the loss of hydrodynamic radius of the nanoparticles. Both cryo-TEM 
and AFM confirmed the disc-shape of the Gelucire nanoparticles. The high aspect ratio in 
combination with the disc shape may contribute to the cellular uptake behaviour of the 
nanoparticles which is discussed later.  
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Figure 5. Tapping mode AFM images of an example of the unloaded F1 (left) and lysozyme 
loaded (right) nanoparticle formulation F1-LYS. 
 
Table 2. Dimensions (as illustrated in Figure 4) of the Gelucire nanoparticles in different 
formulations determined using AFM (n=8-10±SE) 
Formulation 
Unloaded native nanoparticles 
X axis  
(Disc-face diameter 1) 
Y axis 
(Disc-face diameter 2) 
Z axis 
(Thickness) 
F1 84±4.93 62±9.29 3±0.6 
F2 96±7.92 110±13.99 9±1.8 
F3 77±1.41 78.5±4.95 9±0.6 
Formulation 
LYS loaded nanoparticles 
X axis 
(Disc-face diameter 1) 
Y axis 
(Disc-face diameter 2) 
Z axis 
(Thickness) 
F1-LYS 207±5.60 184±6.91 27±0.9 
F3-LYS 142±4.37 139±8.56 12±1.2 
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Protein-loading efficiency and physical stability of disc-shaped gel nanoparticles  
The lysozyme loading efficiency of the nanoparticles showed formulation dependency, but 
particle size independency. For the F1-LYS nanoparticle formulations, the lysozyme was 
encapsulated with higher efficiency (38%) than for the F2-LYS and F3-LYS formulations (33% 
and 29%, respectively). Overall, the encapsulation efficiency of lysozyme in the nanoparticle 
formulations decreases with increasing water content in the bulk gel used to prepare the 
nanoparticles. This may indicate that the encapsulation efficiency may be related to the 
different microstructures of the bulk gels (Codoni et al., 2015). 
 
The physical stabilities of the gel nanoparticle formulations were studied by monitoring the 
particle size of the nanoparticles using DLS. The mean size diameters of all lysozyme-free 
nanoparticles stored at room temperature over a period of two weeks showed no significant 
change (Table 3). At 4°C over a 4-month storage period, no particle size changes were observed 
for any of the formulations indicating that no aggregation or degradation of the particles 
occurred over these time frames. For the formulations loaded with lysozyme, despite little 
change being observed in particle size, a precipitate was observed after 14 days of aging at 
room temperature for the F1-LYS nanoparticles (Table 4). This is likely to be associated with 
the lysozyme instability at room temperature in solution. However, the lysozyme-loaded 
nanoparticles stored at 4 °C were stable over the period of 4 months with no precipitation or 
significant particle size change.  
Table 3. Hydrodynamic size distribution (d.nm) of the unloaded nanoparticles stored at 
different temperatures and monitored overtime using DLS (n=3; NA= Not Analysed) 
Formulations 
stored at 4°C 
Population 1 Population 2 
Time (days) Time (days) 
 7 14 30 120 7 14 30 120 
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F1 — — — — 163±3.15  157±2.35  153±0.94  179±35.37  
F2 20±0.19 18±0.52 NA 19±0.68 160±1.54  159±3.18  NA  163±9.41  
F3 17±0.43 17±0.35 NA 16±2.75 153±4.12  156±2.74  NA  152±5.81  
Formulations 
Stored at 20°C 
Time (days) Time (days) 
1 2 7 14 1 2 7 14 
F1 — — — — 151±4.88 154±3.92 160±5.45  162±2.82  
F2 21±0.89 19±1.47 19±0.39 19±0.60 163±2.50  161±1.14  161±0.37  161±0.88  
F3 17±0.47 17±0.61 17±0.35 17±0.60 158±1.79  160±0.06  157±0.27  156±0.41  
 
Table 4. Hydrodynamic size distribution (d.nm) of the lysozyme loaded gel nanoparticles 
stored at different temperatures and monitored overtime using DLS (n=3; NA= Not Analysed) 
Formulations 
stored at 4°C 
Population 1 Population 2 
Time (days) Time (days) 
 7 14 30 120 7 14 30 120 
F1-LYS — — — — 147±4.28  151±1.86  148±0.91  151±1.11 
F2-LYS 18±0.27 18±2.09 19±1.03 NA 174±7.1  178±3.97  177±1.08  NA  
F3-LYS 17±0.55 17±0.68 17±0.26 NA 139±4.04  136±4.04  139±0.05  NA  
Formulations 
Stored at 20°C 
Time (days) Time (days) 
1 2 7 14 1 2 7 14 
F1-LYS — — — — 155±9.18  150±2.57  NA  NA 
F2-LYS 18±0.27 18±2.09 19±1.03 — 183±0.74  NA  NA  179±3.70  
F3-LYS 17±0.27 18±0.48 18±0.36 17±0.34 139±4.74  138±2.46  143±2.78 146±5.51  
 
Incorporation of lysozyme into the gel nanoparticles may affect its biological activity. 
Therefore the retained biological activities (RBA%) of lysozyme in different gel nanoparticles 
were measured using the micrococcus lysodeikticus assay. As shown in Table 5, the native 
lysozyme solution retains 46% activity at room temperature immediately after preparation. 
After incorporation into the gel nanoparticles, the activity increased to 59% for F1-LYS, but 
reduced to ~20% for F2-LYS and F3-LYS (which were prepared from the gels with higher 
water content). It is noted that F1-LYS also has the highest lysozyme encapsulation efficiency. 
The higher retained activity in the formulation F1-LYS may indicate that the formulation 
protects the lysozyme from degradation and helps to retain its activity. 
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Table 5. Lysozyme loading capacity and retained biological activity (% RBA) in the Gelucire 
gel nanoparticles 
Formulations Loading 
capacity (%) 
% RBA 
F1-LYS 38 59 
F2-LYS 33 21 
F3-LYS 29 19 
 
 
Near UV circular dichroism was further used to investigate any tertiary structural changes of 
lysozyme following its incorporation into the gel nanoparticles. In the near UV region, the 
spectrum arises from the aromatic amino acids of the proteins, such as Tryptophan (Trp), 
Tyrosine (Tyr), Phenylalanine (Phe) and disulfide bridges. In general, Trp shows a peak in the 
region between 290 and 305 nm, the Tyr between 275 and 282 nm and the Phe between 255 
and 270 nm (Kelly et al., 2005). In a lysozyme molecule, the Trp is the most present aromatic 
amino acid with 6 residues per molecule, while the Tyr and Phe have 3 residues each (Jollès, 
1969). CD spectra (Figure 6) were obtained from the aqueous suspensions of F1-LYS, F2-LYS 
and F3-LYS nanoparticles. Aqueous lysozyme solution and unloaded nanoparticles 
suspensions were also analysed as controls. The peaks at 290 nm, associated with the Trp 
residues, are visible in the spectra of all formulations. From the CD spectra it is clear that 
lysozyme retains its tertiary structure in the nanoparticles F2-LYS and F3-LYS, which were 
prepared from the gels with higher water contents, while subtle differences in peaks associated 
the Phe are noted for formulations F1-LYS. In formulations F1-LYS the peak at 284 nm is less 
intense, but the peak at 281 nm is more evident. However, despite the slight alternation of the 
tertiary structure of the lysozyme, F1-LYS nanoparticles still ensures the retaining of the 
biological activity of lysozyme in the formulations, which indicates the alternation is 
insignificant to the biological activity of lysozyme. 
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Figure 6. Near UV CD spectra of lysozyme solution and lysozyme-loaded nanoparticles 
 
Building molecular model of Gelucire nanoparticles  
Using the physicochemical characterisation obtained above in combination with the molecular 
properties of Gelucire reported in literature (Brubach et al., 2004), the structure of the protein 
loaded Gelucire nanoparticles is proposed in Figure 7. Because the nanoparticles are in aqueous 
solution, the polar head of the glycerides and the PEG chains are likely to be located on the 
surface of the particles, while the hydrophobic fatty acid chains (C16 and C18) are enclosed in 
the inner compartment of the nanoparticles. The presence of the free low molecular PEG (MW 
1500) on the surface of the nanoparticles could also explain the good physical stability of the 
formulations (Date et al., 2011). The nanoparticles were confirmed to have a disc-like shape 
by cryo-TEM and AFM. The thickness of the nanoparticles agrees well with the length of the 
glycerides aliphatic chains (4.5-5 nm) indicating the interpenetration nature of glycerides in 
these nano-discs (Brubach et al., 2004). This also implies that these nano-discs are not likely 
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to have a hydrophilic centre as with the classic bilayer, liposome type of colloid, but are more 
likely to have a hydrophobic core which could act as effective encapsulation/solubilisation 
compartments for poorly soluble compounds. This was confirmed by the 100% encapsulation 
efficiency of Coumarin-6, a hydrophobic compound that can also be used as fluorescent dye, 
in the Gelucire nanoparticles.  
 
Figure 7. Schematic illustration of nanostructure of the disc-shaped Gelcuire 50/13 gel 
nanoparticles loaded with model protein drug.  
 
As the nanoparticles are disc-like shape with restricted dimensions, hydrophilic 
macromolecules such as lysozyme cannot be fully loaded within the hydrophobic interior of 
the nanoparticles. Instead, it is more likely that lysozyme may interact with the polar part of 
the surface of the nanoparticles. This interaction may anchor the lysozyme molecules at the 
surface of the nanoparticles. As a result, the loading of lysozyme increases the size of the 
nanoparticles. However, a relatively low encapsulation efficiency would be expected in this 
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scenario as only the nanoparticle surfaces are used to load the protein, thus per particle only 
limited number of lysozyme molecules can be loaded. This also explains the reduced physical 
stability of lysozyme-loaded nanoparticles. The surface adsorbed proteins are likely to increase 
aggregation between particles.  
 
In vitro cytotoxicity and cellular uptake of disc-shaped gel nanoparticles  
As the F1 nanoparticle formulation has many promising properties such as good physical 
stability and encapsulation efficiency and a high level of retained activity of the encapsulated 
lysozyme, its potential as carrier for protein delivery was further explored. The in vitro 
cytotoxicity of the unloaded nanoparticle formulation F1 was tested using a model human lung 
epithelial cell line, H292 and a human colon epithelial cell line, Caco-2. As seen in Figure 7a, 
the F1 formulation with a concentration of 600 µg/ml of total Gelucire was toxic to H292 cells, 
reducing cell viability in the MTS assay by 71%. The results of the other dilutions (up to 300 
µg/ml) of the placebo F1 nanoparticles showed satisfactory cell viability by MTS assay 
(Figures 8a). The effect of the F1 nanoparticle suspension on Caco-2 cell viability was also 
assessed by the MTS assay. As seen in Figure 8b, Caco-2 cells show better tolerance to Gelucire 
nanoparticles than H292 cells. No cytotoxicity was observed even at a 600 µg/ml concentration.  
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Figure 8. In vitro cell viability of (a) H292 cells and (b) Caco-2 cells incubated with F1 
nanoparticle suspensions with different nanoparticle concentrations at 37°C for 24 hours as 
determined by the MTS assay. Viability is calculated as a percentage of the control (n=3).  
 
The in vitro cell uptake of formulation F1 was investigated using Caco-2 cells. In order to be 
able to assess uptake, fluorescently labelled nanoparticles containing Coumarin-6 were 
prepared. The labelled F1 nanoparticle dilutions with final concentrations of total Gelucire of 
300 and 120 µg/ml were used to incubate Caco-2 cell monolayers. As seen in Figure 8a and b, 
after 15 minutes of incubation, it is evident that the cellular internalisation is significant. No 
significant differences were observed after 120 minutes of incubation indicating the uptake is 
rapid and complete within the first 15 minutes of exposure to the nanoparticles. The non-toxic 
and rapid internalisation features of the nanoparticles are further demonstrated by non-changed 
results of F1 nanoparticles after 4 and 24 hours incubation periods in Figure 9.  
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Figure 9. Fluorescent light microscopic images of in vitro Caco-2 cellular uptake of the F1 
nanoparticles from dilutions (a) D1 and (b) D4 after 15 minutes of incubation; and (c) D2 
after 30 minutes of incubation (d) D2 after 4 hours of incubation and (e) D2 after 24 hours 
incubation. Images of a-b, c-d, and e were taken using objectives with 10X, 40X, and 63X 
magnification, respectively. 
 
Although the mechanism by which the nanoparticles were taken up by the Caco-2 cells remains 
unclear and further studies will be required, it is most likely that Coumarin-6 uptake occurred 
when loaded within the nanoparticles. Li and co-workers (2011) reported similar results on the 
cellular uptake of Coumarin 6-loaded liposomes modified by Pluronic. The study suggests that 
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due to high hydrophobicity, the amount of Coumarin 6 detected within the cells should be taken 
up through the interaction between the cells and liposomes.  Therefore, the possibility that 
Coumarin 6 diffused within the cells after being released from the liposomes was excluded. A 
similar mechanism would also be expected to apply in this case. More importantly, the disc-
shape and high aspect ratio of the Gelucire nanoparticles is expected to also contribute to the 
rapid internalisation of the nanoparticles. As reported by Agarwal and co-workers (2013), the 
disc-shaped hydrophilic nanoparticles with high aspect ratios have preferable internalisation in 
vitro conditions for mammalian epithelial and immune cells. This rapid internalisation in vitro 
has been attributed to a complex interplay of three shape- and size-dependent parameters 
including particle surface area available for cell contact, strain energy for membrane 
deformation, and local particle concentration at the cell membrane (Agarwal et al., 2013).  
Conclusions 
This study has demonstrated the ability of Gelucire 50/13 gels to be mechanically fragmented 
into stable disc-shaped nanoparticles. The unique preparation method of the disc-shape 
nanoparticles reported in this study is relatively inexpensive, organic solvent free and does not 
require the addition of any stabilisers. The nanoparticles are with DLS measured mean size 
between 20-300nm and polydispersity of the disc-shape nanoparticles showed formulation 
(water content in the bulk gel) dependency. All characterisation techniques used including cryo-
TEM, DLS and AFM showed good agreement on the size and shape analysis of the nano-discs. 
All formulations (with and without lysozyme) showed good physical stability at 4ºC, however 
lysozyme loading led to an increased tendency for aggregation on storage at room temperature. 
Lysozyme was used as model protein loaded to the nanoparticles. A good efficiency of loading 
of the lysozyme was achieved with nearly 60% retained biological activity of lysozyme in the 
formulations with higher Gelucire content. These formulations showed increased particle size 
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with a larger disc surface which may contribute to accommodate a larger amount of lysozyme 
in comparison to the nano-discs with smaller surface areas. The nanoparticles were shown to 
be non-toxic to the H292 cells up to 300 μg/ml Gelucire concentration, and at least 600 μg/ml 
for the Caco-2 cells. The cellular uptake of the nanoparticles by Caco-2 cells is rapid and stable 
up to 24 hours. The rapid cellular uptake was attributed to the disc-shape and high aspect ratio 
of the gel nanoparticles. The outcome of this study provides prove-of-concept evidence of the 
potential use of this ready-to-use nano-disc formulation for macromolecule delivery.  
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